User profiles for Aaron B. Waxman
Aaron WaxmanAssociate Professor of Medicine, Harvard Medical School Verified email at bwh.harvard.edu Cited by 9967 |
[HTML][HTML] Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension
Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-…
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-…
Interleukin-6 overexpression induces pulmonary hypertension
…, N Kolliputi, EJ Mark, CA Hales, AB Waxman - Circulation …, 2009 - Am Heart Assoc
Inflammatory cytokine interleukin (IL)-6 is elevated in the serum and lungs of patients with
pulmonary artery hypertension (PAH). Several animal models of PAH cite the potential role of …
pulmonary artery hypertension (PAH). Several animal models of PAH cite the potential role of …
Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing
…, M Gulati, JD Possick, DM Systrom, AB Waxman - Chest, 2022 - Elsevier
Background Some patients with COVID-19 who have recovered from the acute infection
after experiencing only mild symptoms continue to exhibit persistent exertional limitation that …
after experiencing only mild symptoms continue to exhibit persistent exertional limitation that …
Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation
…, FRM Causland, SS Waikar, AB Waxman… - PLoS …, 2013 - journals.plos.org
Background Mitochondrial DNA (mtDNA) is a critical activator of inflammation and the innate
immune system. However, mtDNA level has not been tested for its role as a biomarker in …
immune system. However, mtDNA level has not been tested for its role as a biomarker in …
Exercise-induced pulmonary arterial hypertension
JJ Tolle, AB Waxman, TL Van Horn… - Circulation, 2008 - Am Heart Assoc
Background— The clinical relevance of exercise-induced pulmonary arterial hypertension (PAH)
is uncertain, and its existence has never been well studied by direct measurements of …
is uncertain, and its existence has never been well studied by direct measurements of …
Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension
…, DJ Ross, KJ Haley, AB Waxman… - The Journal of …, 2016 - Am Soc Clin Investig
Dysregulation of vascular stiffness and cellular metabolism occurs early in pulmonary
hypertension (PH). However, the mechanisms by which biophysical properties of the vascular …
hypertension (PH). However, the mechanisms by which biophysical properties of the vascular …
MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach
Background— Pulmonary hypertension (PH) is driven by diverse pathogenic etiologies. Owing
to their pleiotropic actions, microRNA molecules are potential candidates for coordinated …
to their pleiotropic actions, microRNA molecules are potential candidates for coordinated …
Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension
Development of the vascular disease pulmonary hypertension (PH) involves disparate
molecular pathways that span multiple cell types. MicroRNAs (miRNAs) may coordinately …
molecular pathways that span multiple cell types. MicroRNAs (miRNAs) may coordinately …
[PDF][PDF] Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-miR-130/301 circuit
…, JR Fineman, SO Vargas, KJ Haley, AB Waxman… - Cell reports, 2015 - cell.com
Pulmonary hypertension (PH) is a deadly vascular disease with enigmatic molecular origins.
We found that vascular extracellular matrix (ECM) remodeling and stiffening are early and …
We found that vascular extracellular matrix (ECM) remodeling and stiffening are early and …
Interleukin-6–induced protection in hyperoxic acute lung injury
NS Ward, AB Waxman, RJ Homer… - American journal of …, 2000 - atsjournals.org
Hyperoxic lung injury is commonly encountered in patients who require treatment with high
concentrations of inspired oxygen. To determine whether interleukin (IL)-6 is protective in …
concentrations of inspired oxygen. To determine whether interleukin (IL)-6 is protective in …